Biochemical Engineering
Cytiva Acquires CEVEC, Boosts Cell Line Development Capabilities
10th October 2022
Cytiva has acquired CEVEC Pharmaceuticals, a Germany-based provider of high-performance cell line development and viral vector manufacturing technologies. With this acquisition, Cytiva gains CEVEC’s scalable producer cell lines for vectors based on adeno-associated virus and adenovirus, two widely used vectors for gene therapy delivery. Source Biopharm International 10/10/2022
Back to group news